Americans are pouring an estimated $1 to $3 billion into unapproved injectable peptides, laboratory made comp0unds that mimic the amino acids the body produces naturally. Products with names like MOTS-c, BPC-157, and KPV are marketed with promises of bigger muscles, faster healing, and a longer life, fueling a surge in popularity even as regulators warn the science hasn’t caught up with the sales pitch.
According to sources, until 2023, Americans could obtain some injectable peptides from compounding pharmacies with a doctor’s prescription. These businesses mix m3dications using ingredients from FDA-inspected facilities, though the dr*gs themselves are typically not FDA-approved. That year, the Biden administration banned compounding pharmacies from selling 20 peptides, citing significant safety risks stemming from a lack of human testing.
The ban outraged peptide users, including podcaster Joe Rogan. “There is no danger that these things are causing. There’s no public health concern. There’s no people dropping dead,” Rogan said.
Health and Human Services Secretary Robert F. Kennedy Jr. has echoed that enthusiasm: “I’m a big fan of peptides. I’ve used them myself, and used them with really good effect, with a couple of injuries.”
Rather than curbing demand, the ban pushed buyers toward the gray and black markets. “I mean, we created the black market,” RFK Jr. noted.
As HHS Secretary, Kennedy appointed new members to an FDA advisory committee, which voted in July to reverse much of the previous ban and allow seven peptides to be sold at compounding pharmacies.
Kennedy argues that peptides bought this way would be safer than black market alternatives: “You know, you’re getting a good product. You know, you’re getting what you bought.”
Critics point out that six of the committee members came from the peptide industry itself, raising concerns about the process.
“Anytime you stack the deck, I have worries,” longevity expert Dr Steven Gundry said. Doctors also caution that while peptides like insulin and GLP-1 treatments are well studied and FDA-approved, many newer synthetic versions lack human trials. “Sometimes we rush into these things,” he warned, adding that growth-promoting effects in some peptides could potentially trigger genes linked to cancer.
Patients will still need a doctor’s prescription to obtain peptides from a compounding pharmacy, and not every doctor is willing to write one. As Gundry put it, “If it sounds too good to be true, it usually is too good to be true.”
It remains unclear when the FDA will act on the committee’s recommendation, though the agency often follows such advice.
